In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 251 to 275 of 424

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Obesity: prevention and lifestyle management (QS update)	Quality standard	TBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]	Technology appraisal guidance	TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]	Technology appraisal guidance	TBC
Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]	Technology appraisal guidance	TBC
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]	Technology appraisal guidance	TBC
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]	Technology appraisal guidance	TBC
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]	Highly specialised technology	TBC
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423	Technology appraisal guidance	13 August 2025
Omburtamab for treating relapsed neuroblastoma [ID1664]	Technology appraisal guidance	TBC
One-piece closed bags for adults with a colostomy: Late Stage Assessment	Health technology evaluation	TBC
Optical Coherence Tomography to guide percutaneous coronary intervention	Interventional procedures guidance	TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]	Technology appraisal guidance	TBC
OrganOx metra for liver transplant [ID5116]	Technology appraisal guidance	TBC
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]	Technology appraisal guidance	TBC
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]	Technology appraisal guidance	20 August 2025
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]	Technology appraisal guidance	TBC
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)	NICE guideline	TBC
Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]	Technology appraisal guidance	TBC
Ovarian cancer QS update	Quality standard	5 February 2025
Overweight and obesity management	NICE guideline	TBC
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]	Technology appraisal guidance	TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]	Technology appraisal guidance	TBC
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]	Technology appraisal guidance	16 July 2025
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]	Highly specialised technology	TBC
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]	Highly specialised technology	TBC

Results per page

10
25
50
All